Navidea biopharmaceuticals appoints joshua wilson to the board of directors; announces dates related to its 2022 annual meeting of stockholders

Dublin, ohio--(business wire)--navidea biopharmaceuticals, inc. (nyse american: navb) (“navidea” or the “company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced the appointment of joshua (“josh”) wilson to its board of directors, effective september 30, 2022, with a term ending concurrently with the company's 2024 annual stockholders' meeting. mr. wilson is a seasoned banking and finance executive with more than 23 years of fi
NAVB Ratings Summary
NAVB Quant Ranking